Skip Navigation
Suburban Hospital
 
 
 
In This Section      
Print This Page

Research Trials: Oncology

For more information, please contact Suburban Hospital Oncology Research:
Barbara Squiller: 301-896-2719
Melissa Hyman: 301-896-3221

TopicStudy NamePrincipal Investigator
BreastProspective Evaluation of the Incidence and Severity of Taxane-Induced Nail Changes in Cancer Treatment.
Call 301-896-2719 or 301-896-3221.
Carolyn Hendricks, M.D.
BreastA Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer. Learn More.Carolyn Hendricks, M.D.
BreastPhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer Learn MoreCarolyn Hendricks, M.D.
CancerPresenting Patient-Reported Outcomes Data to Improve Patient and Clinician Understanding and Use Learn MoreCarolyn Hendricks, M.D.
LiverHumanitarian Use of Intra-arterial Y-90 TheraSpheres for Hepatocellular Carcinoma or Hepatic Metastases from Solid Tumors
Call 301-896-2719 or 301-896-3221.
Andrew Hines, M.D.
BreastMolecular Genetic Studies in Cancer
Call 301-896-2719 or 301-896-3221.
Carolyn Hendricks, M.D.
BreastA Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer Learn MoreCarolyn Hendricks, M.D.
BreastA Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less Learn MoreCarolyn Hendricks, M.D.
BreastPhase II placebo-controlled trial of lisinopril and Coreg CR® to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin®) Learn MoreCarolyn Hendricks, M.D.
BreastProspective Evaluation of the Incidence and Severity of Taxane-Induced Nail Changes in Cancer Treatment. J1218Carolyn Hendricks, M.D.
BreastA Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)- Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer. S1202 Learn moreCarolyn Hendricks, M.D.
BreastA Randomized Phase II Study of Partial Breast Irradation and Sequential vs. Concurrent Chemotherapy in Women with ER Negative Early Stage Breast Cancer. Learn moreSusan Stinson, M.D.
ProstateStereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate. Learn moreStephen Greco, M.D.
BreastA Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms ( AIMSS). Learn moreCarolyn B. Hendricks, M.D.
BreastA Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA) Learn moreCarolyn B. Hendricks, M.D.
CancerSTAR ™ Tumor Ablation System Prospective Clinical Series. Please call 301-896-2719 or 301-896-3221.Bradley Dick, M.D.
Indoor posed shot of the five-person Oncology Research Team Oncology Research Team

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer